Preparation and in vitro evaluation of etoposide-loaded PLGA microspheres for pulmonary drug delivery

Drug Delivery

Volumn 21, Issue 3, 2014, Pages 185-192

  Feng, Ruihua ^a   Zhang, Zhiyue ^a   Li, Zhongwen ^b   Huang, Guihua ^a  

^a SHANDONG UNIVERSITY   (China)

^b Shandong Medical College   (China)

Author keywords

Etoposide; in vitro drug release; Physicochemical characteristics and micromeritics properties; PLGA microspheres; Pulmonary drug delivery

Indexed keywords

ETOPOSIDE; MICROSPHERE; POLYGLACTIN; ANTINEOPLASTIC AGENT; DELAYED RELEASE FORMULATION; DRUG CARRIER; LACTIC ACID; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ARTICLE; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG SCREENING; DRUG STABILITY; EMULSION; ENCAPSULATION; EVAPORATION; FREEZE DRYING; HUMAN; IN VITRO STUDY; LUNG DISEASE; LUNG SMALL CELL CANCER; MORPHOLOGY; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PULMONARY DRUG DELIVERY; SURFACE PROPERTY; CHEMICAL MODEL; CHEMISTRY; DELAYED RELEASE FORMULATION; INHALATIONAL DRUG ADMINISTRATION; KINETICS; MEDICINAL CHEMISTRY; PARTICLE SIZE; PHARMACEUTICS; PROCEDURES; SOLUBILITY;

ADMINISTRATION, INHALATION; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; ETOPOSIDE; KINETICS; LACTIC ACID; MICROSPHERES; MODELS, CHEMICAL; PARTICLE SIZE; POLYGLYCOLIC ACID; SOLUBILITY; SURFACE PROPERTIES; TECHNOLOGY, PHARMACEUTICAL;

EID: 84899752219     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2013.840813     Document Type: Article

References (38)

1. Aisner J, Lee EJ. (1991). Etoposide. Current and future status. Cancer 67:215-9
2. Anderson JM, Shive MS. (2012). Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev 64:72-82
3. Bi R. (2008). Studies on dry powder inhalation of insulin loaded solid lipid nanoparticles. Shandong: Shandong University
4. Calame W, Van Der Waals R, Douwes-Idema N, et al. (1988). Antibacterial effect of etoposide in vitro. Antimicrob Agents Chemother 32:1456-7
5. Costa P, Sousa Lobo JM. (2001). Modeling and comparison of dissolution profiles. Eur J Pharm Sci 13:123-33
6. Diab R, Brillault J, Bardy A, et al. (2012). Formulation and in vitro characterization of inhalable polyvinyl alcohol-free rifampicin-loaded PLGA microspheres prepared with sucrose palmitate as stabilizer: Efficiency for ex vivo alveolar macrophage targeting. Int J Pharm 436: 833-9
7. Doan T, Couet W, Olivier J. (2011). Formulation and in vitro characterization of inhalable rifampicin-loaded PLGA microspheres for sustained lung delivery. Int J Pharm 414:112-7
8. Gao J. 2005. Study on thymopentin(Tp5) dry powder inhalations for pulmonary delivery and their pharmacodynamics. Shanghai: Second Military Medical University
9. Giovagnoli S, Blasi P, Schoubben A, et al. (2007). Preparation of large porous biodegradable microspheres by using a simple doubleemulsion method for capreomycin sulfate pulmonary delivery. Int J Pharm 333:103-11
10. Han B, Wang HT, Liu HY, et al. (2010). Preparation of pingyangmycin PLGA microspheres and related in vitro/in vivo studies. Int J Pharm 398:130-6
11. Hande KR. (1998). Etoposide: Four decades of development of a topoisomerase II inhibitor. Eur J Cancer 34:1514-21
12. Haznedar S, Dortunc B. (2004). Preparation and in vitro evaluation of Eudragit microspheres containing acetazolamide. Int J Pharm 269: 131-40
13. Lam JKW, Liang W, Chan HK. (2012). Pulmonary delivery of therapeutic siRNA. Adv Drug Deliv Rev 64:1-15
14. Lee J, Oh YJ, Lee SK, et al. (2010). Facile control of porous structures of polymer microspheres using an osmotic agent for pulmonary delivery. J Control Release 146:61-7
15. Li X, Tang Y, Zhu J. (2010). Progress on dry powder inhalers. Chinese J Pharm 41:219-23
16. Louey MD, Razia S, Stewart PJ. (2003). Influence of physico-chemical carrier properties on the in vitro aerosol deposition from interactive mixtures. Int J Pharm 252:87-98
17. Nath SD, Son S, Sadiasa A, et al. (2013). Preparation and characterization of PLGA microspheres by the electrospraying method for delivering simvastatin for bone regeneration. Int J Pharm 443: 87-94
18. Patlolla R, Vobalaboina V. (2005). Pharmacokinetics and tissue distribution of etoposide delivered in parenteral emulsion. J Pharm Sci 94: 437-45
19. Patton JS, Bukar J, Nagarajan S. (1999). Inhaled insulin. Adv Drug Deliv Rev 35:235-47
20. Qian WY, Sun DM, Zhu RR, et al. (2012). pH-sensitive strontium carbonate nanoparticles as new anticancer vehicles for controlled etoposide release. Int J Nanomed 7:5781-92
21. Schaefer MJ, Singh J. (2001). Effect of additives on stability of etoposide in PLGA microspheres. Drug Dev Ind Pharm 27: 345-50
22. Schaefer MJ, Singh J. (2002). Effect of tricaprin on the physical characteristics and in vitro release of etoposide from PLGA microspheres. Biomaterials 23:3465-71
23. Sengupta S, Tyagi P, Velpandian T, et al. (2000). Etoposide encapsulated in positively charged liposomes: Pharmacokinetic studies in mice and formulation stability studies. Pharmacol Res 42: 459-64
24. Sham JOH, Zhang Y, Finlay WH, et al. (2004). Formulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lung. Int J Pharm 269:457-67
25. Silva LFC, Kasten G, de Campos CEM, et al. (2013). Preparation and characterization of quercetin-loaded solid lipid microparticles for pulmonary delivery. Powder Technol 239:183-92
26. Sinha VR, Singla AK, Wadhawan S, et al. (2004). Chitosan microspheres as a potential carrier for drugs. Int J Pharm 274:1-33
27. Steckel H, Brandes HG. (2004). A novel spray-drying technique to produce low density particles for pulmonary delivery. Int J Pharm 278:187-95
28. Tamber H, Johansen P, Merkle HP, Gander B. (2005). Formulation aspects of biodegradable polymeric microspheres for antigen delivery. Adv Drug Deliv Rev 57:357-76
29. van Meerbeeck JP, Fennell DA, De Ruysscher DK. (2011). Small-cell lung cancer. Lancet 378:1741-55
30. Vanbever R, Mintzes JD, Wang J, et al. (1999). Formulation and physical characterization of large porous particles for inhalation. Pharm Res 16:1735-42
31. White S, Bennett DB, Cheu S, et al. (2005). EXUBERA-: Pharmaceutical development of a novel product for pulmonary delivery of insulin. Diabetes Technol Ther 7:896-906
32. Xu Q, Czernuszka JT. (2008). Controlled release of amoxicillin from hydroxyapatite-coated poly (lactic-co-glycolic acid) microspheres. J Control Release 127:146-53
33. Yadav KS, Chuttani K, Mishra AK, Sawant KK. (2010). Long circulating nanoparticles of etoposide using PLGA-MPEG and PLGA-pluronic block copolymers: Characterization, drug-release, blood-clearance, and biodistribution studies. Drug Dev Res 71: 228-39
34. Yang Y, Bajaj N, Xu P, et al. (2009). Development of highly porous large PLGA microparticles for pulmonary drug delivery. Biomaterials 30: 1947-53
35. Yen SY, Sung KC, Wang JJ, et al. (2001). Controlled release of nalbuphine propionate from biodegradable microspheres: In vitro and in vivo studies. Int J Pharm 220:91-9
36. Zhang Z, Bi X, Li H, et al. (2011). Enhanced targeting efficiency of PLGA microspheres loaded with Lornoxicam for intra-Articular administration. Drug Deliv 18:536-44
37. Zhang Z, Huang G. (2012). Intra-Articular lornoxicam loaded PLGA microspheres: Enhanced therapeutic efficiency and decreased systemic toxicity in the treatment of osteoarthritis. Drug Deliv 19:255-63
38. Zolnik BS, Burgess DJ. (2007). Effect of acidic pH on PLGA microsphere degradation and release. J Control Release 122: 338-44